NCT01398917

Brief Summary

Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of the biliary tract of unknown origin. Around 50% of patients develop during their disease course narrowing of the main bile duct with corresponding increase in symptoms such as itching, jaundice and abdominal pain. These narrowings can be treated by balloon dilatation or temporary insertion of a plastic endoprosthesis. However, it is not known which of these two therapeutic modalities is best. This study aims to compare both techniques in order to determine which is best in terms of postponing recurrence of the narrowing, safety and costs.

Trial Health

47
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started May 2011

Typical duration for phase_3

Geographic Reach
4 countries

4 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 25, 2011

Completed
6 days until next milestone

Study Start

First participant enrolled

May 1, 2011

Completed
3 months until next milestone

First Posted

Study publicly available on registry

July 21, 2011

Completed
3.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2015

Completed
Last Updated

July 9, 2012

Status Verified

July 1, 2012

Enrollment Period

4 years

First QC Date

April 25, 2011

Last Update Submit

July 5, 2012

Conditions

Keywords

pscdominant stricture

Outcome Measures

Primary Outcomes (1)

  • recurrence-free interval of the primary dominant stricture

    24 months

Secondary Outcomes (1)

  • number of patients with adverse events in both groups

    3 months

Study Arms (2)

short-term stenting

ACTIVE COMPARATOR

one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks

Procedure: plastic endoprosthesis

balloon dilatation

ACTIVE COMPARATOR

4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)

Procedure: balloon dilatation

Interventions

one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks

Also known as: plastic stent
short-term stenting

4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)

Also known as: biliary dilatation balloon
balloon dilatation

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • PSC ascertained with MRCP, ERCP, PTC and/or liver biopsy or
  • PSC highly suspected and to be confirmed with present ERCP
  • Age between 18-75 years
  • Total bilirubin \> 3x ULN or rsie in alkaline phosphatase or bilirubin \> 50% together with increase in cholestatic complaints

You may not qualify if:

  • Prior stenting or balloon-dilatation within last 6 months
  • Clinical signs serious suppurative cholangitis reflected by either fever \> 39.0 °C, tachycardia, leukocytosis and elevated CRP, or fever \> 38,5 C together with purulent bile found during ERCP.
  • Change of ursodeoxycholic acid therapy shorter than two months ago.
  • Inability to give written informed consent
  • Signs of biliary cirrhosis Child-Pugh B or C
  • Estimated transplant-free survival shorter than 2 years as calculated by a Mayo score \< 2
  • Serious suspicion of cholangiocarcinoma, reflected by an imaging study suggestive of metastasis, MRCP with mass lesion with contrast enhancement, rise in CA19.9 of \> 63 U/ml with an absolute value \> 130 U/ml 14 .
  • Signs of current malignancy other than basocellular skin carcinoma.
  • Inability to give informed consent.
  • Life expectancy \< 24 months.
  • Use of antibiotics in previous 4 weeks.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

UZLeuven

Leuven, Belgium

RECRUITING

Academic Medical Center

Amsterdam, 1100 DE, Netherlands

RECRUITING

Rikshospitalet

Oslo, N-0027, Norway

RECRUITING

Karolinska Institute

Stockholm, 141 86, Sweden

RECRUITING

Related Publications (1)

  • Ponsioen CY, Arnelo U, Bergquist A, Rauws EA, Paulsen V, Cantu P, Parzanese I, De Vries EM, van Munster KN, Said K, Chazouilleres O, Desaint B, Kemgang A, Farkkila M, Van der Merwe S, Van Steenbergen W, Marschall HU, Stotzer PO, Thorburn D, Pereira SP, Aabakken L. No Superiority of Stents vs Balloon Dilatation for Dominant Strictures in Patients With Primary Sclerosing Cholangitis. Gastroenterology. 2018 Sep;155(3):752-759.e5. doi: 10.1053/j.gastro.2018.05.034. Epub 2018 May 24.

MeSH Terms

Conditions

Cholangitis, Sclerosing

Condition Hierarchy (Ancestors)

CholangitisBile Duct DiseasesBiliary Tract DiseasesDigestive System Diseases

Study Officials

  • Cyriel Y Ponsioen, dr.

    Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Cyriel Y Ponsioen, Dr.

CONTACT

Florien M Toxopeus, Drs.

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

April 25, 2011

First Posted

July 21, 2011

Study Start

May 1, 2011

Primary Completion

May 1, 2015

Study Completion

May 1, 2015

Last Updated

July 9, 2012

Record last verified: 2012-07

Locations